Bed bugs: frequently asked questions and answers
Public health guidance on bed bug biology, behaviour, and disease transmission risk.
Hungary NNGYK · HungaryHungary
Regulation
Category
Type
Date
Off-label drug prescribing recommendation for gadoteric acid, gadobutrol, gadoteridol, and gadopiclenol
NNGYK issued off-label prescribing guidance for gadolinium-based contrast agents in dynamic contrast-enhanced MR lymphography in children and young adults.
Hungary NNGYK · HungaryNew national procedure to prevent congenital syphilis
Hungary issues methodological guidance on preventing congenital syphilis, responding to rising cases from 91 in 2025 to 100 in the first eight months of 2026.
Hungary NNGYK · HungaryNNGYK off-label drug use recommendation for alteplase in peripheral arterial and venous catheter-based thrombolytic treatment
NNGYK issued off-label use guidance for alteplase in peripheral arterial and venous catheter-based thrombolytic treatment in adults.
Hungary NNGYK · HungaryNew professional guidance to help inpatient care facilities prepare for heat waves
Guidance on preparing hospital systems for health risks from extreme heat and increased emergency cases during heat waves.
Hungary NNGYK · HungaryAvoiding fraud when ordering pest control services: guidance for consumers
Guidance on selecting legitimate pest-control contractors and avoiding fraudulent operators in the regulated pest-control sector.
Hungary NNGYK · HungarySoHO Regulation: everything you need to know to get started
Informational document on national and regional communication and awareness activities regarding donation of substances of human origin (SoHO).
Hungary NNGYK · HungaryNNGYK off-label prescribing recommendation for tranexamic acid medicines
NNGYK issued guidance on institutional-level authorization for local and intra-articular use of tranexamic acid medicines for bleeding reduction.
Hungary NNGYK · HungaryHealthcare-associated infection institutional data now publicly available
Hungary's NNGYK publishes institutional data on healthcare-associated infections through a new public interactive platform.
Hungary NNGYK · HungaryHungary NNGYK: Triaxis-labelled vaccine authorised for use in Hungary
The pharmaceutical authority authorises use of Triaxis-packaged vaccine batches (same formulation as domestically-named Adacel) for routine school vaccination programmes.
Hungary NNGYK · HungaryNNGYK department head appointed as chair of ECHA Management Board
Dr Szilvia Deim, head of the Hungarian chemical safety authority's Chemical Safety and Competent Authority Division, elected unanimously as chair of the European Chemicals Agency Management Board for two years.
Hungary NNGYK · HungaryEvery step taken at the right time counts – early detection of breast cancer can save lives
Hungary's National Public Health and Pharmacy Centre launches October breast cancer awareness campaign emphasizing early screening and detection.
Hungary NNGYK · HungarySecond-level heat alert in effect from Thursday
Hungary's chief medical officer declares second-level heat alert nationwide from 20–23 August due to temperatures exceeding 30°C.
Hungary NNGYK · HungaryPrevention is in our hands – October 15 is Global Handwashing Day
October 15 marks Global Handwashing Day, emphasizing hand hygiene with soap and water as a simple and effective tool to reduce infectious disease transmission.
Hungary NNGYK · HungaryStaff member Dr. Donát Magyar appointed as titled university associate professor
Munkatársunk, Dr. Magyar Donát 2026. szeptember 7-én címzetes egyetemi docensi kinevezésben részesült a Magyar Agrár- és Élettudományi Egyetemen (MATE). Az elismerés az egyetemmel folytatott több évtizedes kutatói és ...
Hungary NNGYK · HungaryNational surveillance programme for infection monitoring launched in intensive care units
A nationally coordinated surveillance programme for monitoring infections in intensive care units began on 1 July, coordinated by the National Public Health and Pharmacy Centre.
Hungary NNGYK · HungaryInformation on the reporting obligation for signals identified by marketing authorisation holders to the authority
From 1 September 2026, procedures for reporting identified signals (adverse event signals) to the Hungarian medicines authority will change; holders must evaluate and report signals within 15 days.
Hungary NNGYK · HungaryHealthcare-associated infection data to be made publicly available from September
Hungary will publish institutional data on healthcare-associated infections from September using a new methodology developed by the National Public Health and Pharmacy Centre.
Hungary NNGYK · HungaryFree HPV vaccination for schoolchildren: deadline approaching
Hungary extends deadline to September 15 for parents to submit consent forms for free HPV vaccination of seventh-grade students.
Hungary NNGYK · HungaryCall for contributions to special issue marking the 40th anniversary of the Ottawa Charter
Hungarian health promotion professionals invited to contribute experiences and work related to the Ottawa Charter's principles for a jubilee special issue.
Hungary NNGYK · HungaryRagweed pollen season starting soon – prepare in time
Hungary's National Public Health Centre forecasts ragweed pollen will appear nationwide by late July.
Hungary NNGYK · HungaryMajor heat wave arriving from Thursday
A Nemzeti Népegészségügyi és Gyógyszerészeti Központ és a BM Országos Katasztrófavédelmi Főigazgatóság közös közleménye
Hungary NNGYK · HungaryFresh information on supplementary risk minimisation measures
NNGYK announces a pilot project on supplementary risk minimisation measures for safe medicine use from 4 June 2026.
Hungary NNGYK · HungaryHPV vaccination programme organised for 2026/2027 school year in Hungary
Free HPV vaccination offered to seventh-grade girls and boys in Hungary; parental consent required by 15 September 2026.
Hungary NNGYK · HungaryUpdated information on supplementary risk minimisation measures for medicines
NNGYK updated its website information on supplementary risk minimisation measures and programmes for medicines on 16 June 2026.
Hungary NNGYK · HungaryKeytruda (pembrolizumab) approved under accelerated procedure for neoadjuvant treatment of malignant melanoma
Keytruda (pembrolizumab) 25 mg/ml concentrate and 395 mg solution approved under accelerated procedure for neoadjuvant melanoma treatment.
Hungary NNGYK · Hungary
Showing 26 of 26 tracked updates
Health-tech only